Levodopa/Benserazid Neuraxpharm (Benserazide Hydrochloride, Levodopa)

Levodopa/Benserazide, the active ingredient in Levodopa/Benserazid Neuraxpharm, is an antiparkinson agent presented as an oral tablet for systemic administration. It is used to increase central dopamine levels, thereby improving motor symptoms in patients with Parkinson's disease and Parkinsonian syndrome.

GNH USA supplies Levodopa/Benserazid Neuraxpharm as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies and clinics worldwide under stringent quality standards. The product conforms to European Union marketing authorisation requirements and is manufactured in facilities adhering to GMP guidelines.

Levodopa/Benserazide is used in the management of Parkinsonian disorders by restoring dopaminergic activity.

- Parkinson's disease: improves motor function and reduces rigidity and bradykinesia. - Parkinsonian syndrome: alleviates tremor, stiffness and gait disturbances. - Levodopa‑responsive Parkinsonism: provides symptomatic relief when dopamine deficiency is the primary cause.

Levodopa/Benserazide may cause a range of adverse reactions.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Orthostatic hypotension: dizziness upon standing. - Headache: transient cranial discomfort. - Insomnia: difficulty initiating or maintaining sleep. - Dyspepsia: indigestion or abdominal discomfort. - Dry mouth: reduced salivation.

Serious or Rare Side Effects: - Dyskinesia: involuntary, erratic movements. - Psychiatric disturbances: hallucinations, confusion or depression. - Severe hypotension: marked drop in blood pressure requiring medical attention. - Cardiac arrhythmias: irregular heart rhythms, especially in patients with pre‑existing cardiac disease. - Neuroleptic malignant‑like syndrome: rare but life‑threatening reaction with fever and muscle rigidity.

Before initiating therapy, clinicians should consider several safety aspects.

- Blood pressure monitoring: watch for orthostatic drops, especially in the elderly. - Psychiatric assessment: evaluate history of psychosis or depression. - Renal function: adjust dose in patients with severe impairment. - Abrupt discontinuation: avoid sudden stop to prevent withdrawal syndrome. - Concomitant dopamine antagonists: use with caution as they may reduce efficacy. - Store at room temperature: keep in the original container, protect from moisture and light.

Levodopa/Benserazide can interact with several drug classes.

Major Interactions (Avoid): - Non‑selective MAO inhibitors: risk of hypertensive crisis. - Antipsychotics (dopamine blockers): may diminish therapeutic effect. - High‑protein meals: can impair levodopa absorption.

Moderate Interactions (Monitor Closely): - Antihypertensive agents: additive blood‑pressure lowering. - SSRIs and SNRIs: potential for serotonin syndrome. - Iron or vitamin B6 supplements: may reduce levodopa bioavailability. - Diuretics: may affect electrolyte balance and blood pressure.